ABSTRACT
INTRODUCTION
Japanese encephalitis virus (JEV) causes a serious and potentially life-threatening infection of the central nervous system of which children are the most affected.
Although the majority of infections are asymptomatic, the case fatality is estimated at 20-30% in those who develop clinical disease and up to 50% of survivors experience life-long neuropsychiatric sequelae [1, 2] . There is no specific antiviral treatment for JE infection but with the availability of safe effective vaccines that can be integrated into existing childhood vaccination programs in endemic countries, there is an opportunity to reduce the adverse health and economic burden of JEV disease. Currently, there are three commercial vaccines licensed for use in several regions of the world [3] [4] [5] . This review will focus on the live-attenuated JE-chimeric vaccine 
METHOD
The analysis in this article is based on previously conducted studies, and does not involve any new studies of human or animal subjects performed by any of the authors. This review was conducted through a MEDLINE search, limited to the English language, from 1980 to June 2013 using the following search terms and filters: Japanese encephalitis, natural history, virology and vaccine. Manual-search of reference list of relevant studies, clinical trials and reviews was also conducted. [8] and has been isolated in the mosquito vector, Culex tritaeniorhynchus, in China [9] .
Virology of JEV

Transmission Cycle of JEV and Geographic
Distribution
JEV is transmitted in a zoonotic cycle between mosquitoes, water birds and pigs. The principal mosquito vector is the Culex mosquito, in particular, C tritaeniorhynchus, an evening-and night-time biting mosquito [10] . Mosquitoes are zoophilic, feeding on wading birds (herons and egrets) and pigs, which are the primary hosts in the infection cycle. JEV infection causes high-titer viremia in pigs, which are increasingly recognized as the most important ecological reservoir for JE in the amplification and spread of JEV [7] .
Humans are incidental end-hosts in the lifecycle of JEV and not necessary for the maintenance of the viral transmission due to low-titer viremia in humans that is insufficient to infect the biting mosquito vectors. JEV is widely distributed throughout Asia and the Pacific rim, with peak endemicity centered on equatorial Asia and seasonal epidemics occurring in the more temperate regions of southeast Asia, India, Japan, Korea, Taiwan and mainland China ( Fig. 1 ) [11] [12] [13] [14] .
In the tropical and subtropical regions of Asia, transmission of JEV occurs year-round, peaking during the rainy season, while in the northern temperate regions, JE follows an epidemic pattern and is more prevalent during and after the monsoon rains in summer and autumn. JE infection in humans has been tracked according to rainfall patterns, mosquito numbers and seroconversion in sentinel animals [15] . More recently, JEV has been identified in the Torres Strait Islands and in the Cape York Peninsula of Far North Queensland in Australia [16] [17] [18] and also in Tibet, formerly believed to be a non-endemic region [19] .
Incidence of JE in Endemic Populations and Travelers
It has been difficult to accurately determine the incidence of JE infection because the majority of infections are subclinical [20] . The extent to which measures to control the mosquito vector, improvements in agricultural and commercial animal husbandry practices and JE vaccination programs have impacted on the overall incidence of JE infection has not been accurately quantified. In 2011, the World Health Organization (WHO) surveillance data estimated that the incidence of JE infection was 1.8 per 100,000 persons, approximately 67,900 new cases annually. However, with 75% of cases occurring in children, the annual incidence in those aged 0-14 years was 5.4 per 100,000, 3 times higher than the overall incidence [21] .
The expansion of global travel, tourism and economic opportunities in Asia has seen a large number of travelers from non-endemic regions visiting and living in JEV endemic regions, and this population represents an emerging group at risk of acquiring JE infection [22] [23] [24] . [25] . In contrast, Hill and co-workers reported an incidence of 0.2 cases per million travelers [26] while an earlier study in Swiss and British travelers reported an incidence of 1.3 cases per 7.1 million travelers [27] . Even though the incidence is low, travelers from non-endemic However, the motor deficits, movement, behavioral, psychiatric disorders and learning deficits often persist and may take several decades to improve. These long-term sequelae extend the morbidity of the infection well beyond the acute period and add to the health and economic burden to local communities [28] .
Laboratory Diagnosis of JE Infection
Diagnosis of acute JE infection is made by detecting JEV-specific IgM or a fourfold rise in JEV-specific IgG in the serum and cerebrospinal fluid (CSF) by capture enzyme-linked immunosorbent assay (MAC ELISA). JEVspecific IgM antibodies rise rapidly and are detectable in the CSF by day 4 after the onset of symptoms, and by day 7 in the serum, followed by a slower rise in JEV-specific IgG [29, 30] . By day 30 after primary infection, JEVspecific IgG antibodies are detected in the serum in 100% of individuals. However, in endemic regions, JE antibodies may be confounded by cross-reacting antibodies from other flavivirus infection such as dengue, tickborn encephalitis or from previous vaccination against yellow fever or JE [31, 32] . A fourfold or greater rise in JE-specific antibodies between acute and convalescent-phase serum 2-4 weeks apart is useful in confirming acute infection and distinguishing from non-JEV flaviviral crossreacting antibodies. JEV-specific IgM may also be detectable in the CSF and has been associated with a poorer outcome [30] . JEV-specific neutralizing antibodies can also be determined by the plaque reduction neutralization test (PRNT). However, this is a labor-intensive assay and is usually only available in research and reference laboratories.
Although conventional nucleic acid amplification test of CSF and serum are not used to diagnose acute JE because viremia is short-lived and of low titer, recent advances in the real-time RT-PCR technology using loopmediated isothermal amplification (RT-LAMP) could see its use in resource-poor settings [33] .
Real-time RT-LAMP is rapid test and easy to perform using a single tube assay with color detection visible to the naked eye. It has a detection limit as low as 0.1 plaque forming units (pfu). Parida et al. [34] reported a sensitivity and specificity of RT-LAMP of 100% and 86%, respectively, and was able to detect serologically confirmed positive samples missed by conventional RT-PCR. Its utility and advantage over the current serological tests
have not yet been determined.
Treatment of JE
There are no specific antiviral treatments for JE, and any treatments are largely supportive to control seizures, dystonia, cerebral edema and respiratory support. Clinical trials of interferon a-2a, ribavirin and corticosteroids have failed to show improvement in clinical outcome and are not recommended [35] [36] [37] . Prevention of JE by vaccination and vector control measures remains the only enduring options to reduce the incidence of JE.
JE Preventive Vaccine
Until more recently, the prevention of JE infection has relied on the use of an ChimeriVax technology was developed by Chambers et al. [40] at St Louis University (MO, USA) and further developed into the JEchimeric virus at Acambis (Cambridge, UK) [41] before being licensed by Sanofi Pasteur.
Preclinical Testing
The ChimeriVax The durability and efficacy of the neutralizing antibody response to the ChimeriVax TM -JE vaccine were assessed in a 5-year follow-up study [48] . In this study, 202 young healthy participants from non-endemic This study also demonstrated that the vaccine-induced antibodies were capable of In a follow-up study, the durability of vaccine-induced antibody was estimated by statistical modeling [49] . Based on the GMT value at 28-day post-vaccination (GMT 1392 in the ChimeriVax TM -JE group), the rate of antibody decline was gradual enough to confer seroprotection for up to 10 years post- 
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